Idarubicin /ˌaɪdəˈruːbɪsɪn/ or 4-demethoxydaunorubicin is an anthracycline antileukemic drug. It inserts[1] itself into DNA and prevents DNA unwinding by interfering with the enzyme topoisomerase II. It is an analog of daunorubicin, but the absence of a methoxy group increases its fat solubility and cellular uptake.[2] Similar to other anthracyclines, it also induces histone eviction from chromatin.[3]

It belongs to the family of drugs called antitumor antibiotics.

It is currently combined with cytosine arabinoside as a first line treatment of acute myeloid leukemia.[4]

It is used for treatment of acute lymphoblastic leukemia and chronic myelogenous leukemia in blast crisis.[5]

It is distributed under the trade names Zavedos (UK) and Idamycin (USA).

Side effects

Diarrhea, stomach cramps, nausea and vomiting are common among patients treated with idarubicin.[6]

References

  1. ^ Miller JP, Stoodley RJ (2013). "Studies directed towards anthracyclinone syntheses: The use of d-glucose as a chiral auxiliary in asymmetric Diels–Alder reactions". J. Saudi Chem. Soc. 17: 29–42. doi:10.1016/j.jscs.2011.02.019.
  2. ^ "Idamycin Package insert" (PDF). Pfizer. January 2006.
  3. ^ Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, et al. (2013). "Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin". Nature Communications. 4: 1908. Bibcode:2013NatCo...4.1908P. doi:10.1038/ncomms2921. PMC 3674280. PMID 23715267.
  4. ^ Arwanih EY, Louisa M, Rinaldi I, Wanandi SI (December 2022). "Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review". Cureus. 14 (12): e33165. doi:10.7759/cureus.33165. PMC 9885730. PMID 36726936.
  5. ^ Katzung BG (2017-11-30). Basic & clinical pharmacology. McGraw-Hill Education. ISBN 9781259641152. OCLC 1009849139.
  6. ^ "Idarubicin Side Effects: Common, Severe, Long Term". Drugs.com. Retrieved 2019-06-21.
Allikas: https://en.wikipedia.org/wiki/Idarubicin
No tags for this post.